Asvins Lifetechnologies was incorporated in the year 2016 with a vision to enable molecular diagnostics and life sciences solutions on a centralized basis in India. The company is a part of the prestigious 60 year old NSP group having diversified interests in Life sciences, Healthcare diagnostics and Blood Banking solutions.
World-class Products and Services
Asvins has collaborated with one of the leading Molecular Dx company named Biocartis, NV, based in Belgium to get their fastest fully automated Molecular Diagnostics platform named Idylla to the Indian market and accessible to the physicians for early diagnosis less than 3 hours .Idylla, fully automated, real-time Polymerase Chain Reaction (PCR) based molecular diagnostics system, is designed to offer physicians fast access to highly reliable clinical molecular diagnostic information, anywhere and anytime. Idylla™ detects and quantifies multiple DNA or RNA-based biomarkers in a wide variety of patient sample types.
Asvins targeted audience would be Corporate/Private Cancer Hospitals, Super Speciality Hospitals, Government/Semi-Government Medical institutions focussing on cancer care, Corporate/Private Diagnostic service providers, Pharma companies who are providing various drugs for cancer treatment.
Some of the incredible achievements of Asvins Lifetechnologies is, it has been listed by Silicone India magazine as TOP 10 Lifesciences Startup in India and awarded for best Customer Relationship by Biocartis N.V.
Current Scenario of Cancer Disease in India
The most critical issue India is facing is the rate of mortality due to cancer. The value touched an alarming limit of 806000 cases in the last century. Cancer is the second most common disease in India responsible for maximum mortality with about 0.3 million deaths per year. Besides, attempts have been made to describe the main causes of cancer along with their preventive measures. In addition to this, efforts have also been made to predict the effect of increasing number of cancer patients on the Indian economy. In low and middle-income countries, limited access to affordable and quality cancer diagnosis and treatment has contributed to mortality-to-incidence ratios approximately 20% higher than those of industrialized countries.
Company’s Motive is to Overcome the Issues Related to Higher Cost and Turn-around Time
The spending on healthcare is invariably growing faster than the GDP. The rate of growth of healthcare expenditure has exceeded that of GDP. Macroeconomic factors like aging population or insufficient public funding are challenging to both receivers and providers of healthcare. These advanced, automated and integrated technologies widen the application scope of molecular diagnostics, they also lead to high test costs, which are unaffordable to huge sections of patients in India. Besides, lack of healthcare insurance and reimbursement schemes for diagnostics, which usually are not considered as important as drugs, further limits adoption in the region.
Besides that, the turn-around time for the patient to get the results usually after a biopsy sample is collected is almost 5-7 days or even more. It is observed that many patients travel from one part of the country to get their treatments done, but due to long turn-around times of the results, the patients have to wait for their diagnosis reports so that the appropriate therapies can be started. With Asvin’s platform, the company is able to provide the diagnosis reports the same day to the physicians which would enable them to start the appropriate therapies on their patients at an early stage.
Company’s Success is Contributed to Seeking Cancer at Early Stages
The USP of Asvin is to provide fastest solution to the problem related to the field of Cancer diagnosis. With this, the company is able to guide the patient for early treatment of cancer which could save their lives from this deadly disease which is unfortunately at its peak today.
Asvin’s motto says it all. Molecular Diagnostics enables understanding of diseases at much early stage, which is not possible using the traditional methods. The company aims to provide direct access to personalized medicine for patients in India by promoting fully integrated and broadly applicable molecular diagnostics. Their platforms can be used in a wide variety of healthcare settings to enable rapid and high-quality care close to patients.
Integrated Factors that Catalyze Creativity and Innovation at the workspace
Employee Happiness and Positive Work environment is very crucial for success of any Company in the modern world. The company believe in Give positive reinforcement, Show gratitude, Spread happiness, Motivate others, Celebrate wins, Encourage positive thinking, Change the way you respond, Get moving, Encourage fun, Share your gratitude and Engage in random acts of kindness. Combination of all these factors consolidate the foundation of company.
Strategies Followed by Company to have Long-term Customer Relationship
In this competitive world customer relationship and satisfaction is most important factor. So to have an extra advantage over the competitors, the company follows the strategies like engage your customers through website, email messaging, and social media posts and make sure you’re engaging the customers and increasing their personal connection. Find opportunities to meet your customers in person, using experiential marketing techniques to announce, invite, and follow up afterward. Explore their social media influence. The company tries to offer brand experience to its customers and make connections that add value to the customers’ lives, which will in turn make them want to keep buying from you. Make customers feel special. Responding to every concern a customer faces.
Asvin’s Future Plans
At present, Asvins Lifetechnologies is offering complete automated Solid and Liquid biopsies for Lung, Colon and skin cancer. In the near future, they would be dealing in MSI (Micro Satellite Instability) for determining lynch syndrome in Colon cancer, Breast Cancer (BRCA1 and BRCA 2) mutation test and Gene fusion panel for testing variety of other mutations e.g. ALK, ROS1 etc. In the next couple of years, the company plans to expand in the field of Immunology, Microbiology (infectious, respiratory diseases) and genetic Engineering.